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Abstract 
 
No standard of care for patients with recurrent glioblastoma has been defined since 
temozolomide has become the treatment of choice for patients with newly diagnosed 
glioblastoma. This has renewed interest in the use of nitrosourea-based regimens for patients 
with progressive or recurrent disease. The most commonly used regimens are carmustine 
(BCNU) monotherapy or lomustine (CCNU) combined with procarbazine and vincristine 
(PCV). Here we report our institutional experience with nimustine (ACNU) alone (n=14) or 
in combination with other agents (n=18) in 32 patients with glioblastoma treated previously 
with temozolomide. There were no complete and two partial responses. The progression-free 
survival (PFS) rate at 6 months was 20% and the survival rate at 12 months 26%. Grade III or 
IV hematological toxicity was observed in 50% of all patients and led to interruption of 
treatment in 13% of patients. Non-hematological toxicity was moderate to severe and led to 
interruption of treatment in 9% of patients. Thus, in this cohort of patients pretreated with 
temozolomide, ACNU failed to induce a substantial stabilization of disease in recurrent 
glioblastoma, but caused a notable hematotoxicity. This study does not commend ACNU as a 
therapy of first choice for patients with recurrent glioblastomas pretreated with temozolomide. 
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Introduction 
 
The introduction of temozolomide as the standard of care for patients with newly diagnosed 
glioblastoma [1] has resulted in an increased use of temozolomide as the first chemotherapy 
of choice for glioma patients in general. Previously, nitrosourea-based regimens had been 
considered the most active chemotherapy for patients with glioma, although their value had 
remained controversial [2]. The British Medical Research Council (MRC) trial had failed to 
demonstrate superior activity of PCV added to radiotherapy compared with radiotherapy 
alone [3]. The NOA-01 trial of the Neurooncology Working Group of the German Cancer 
Society as well as two smaller series from Japan had reported very promising median survival 
data exceeding 16 months using ACNU-based primary radiochemotherapy regimens, but 
these trials lacked an appropriate control arm [4-6]. A recent meta-analysis also proposed a 
significant survival gain for ACNU in newly diagnosed high-grade gliomas [7]. The 
widespread use of temozolomide in patients with newly diagnosed disease, mostly 
glioblastoma, resulted in a reevaluation of nitrosoureas at progression or recurrence. Larger 
patient series were published for BCNU alone [8] or in combination with procarbazine and 
vincristine (PBV) [9] and for PCV [10, 11]. Here we report our institutional experience with 
ACNU, a less well studied nitrosourea compound mainly used in central Europe and Japan, in 
the treatment of patients with progressive or recurrent gliomas. 
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Methods 
 
We reviewed the records of 32 glioblastoma patients who were treated with ACNU alone or 
in combination between 2003 and 2008 after having failed therapy with temozolomide, or 
suffered recurrence afterwards. All patient charts were used for an analysis of toxicity. 
Patients were treated with ACNU alone (n=14) or in combination with teniposide (n=17) or 
cytarabine (n=1). ACNU was administered in 6-week intervals at 72-90 mg/m2 i.v. depending 
on whether it was used alone or in combination and depending on type and extent, as well as 
toxicity associated with prior treatment. Charts were evaluated for neuroimaging, prior 
therapy, Karnofsky performance score (KPS) before ACNU, toxicity and dose of steroids. 
Toxicity was classified according to the common terminology criteria for adverse events 
(CTCAE) version 3.0. Response was assessed retrospectively according to MacDonald 
criteria [12]. Factors influencing time to progression and death were analyzed by univariate 
Log Rank tests with Kaplan Meier curves and by multivariate COX analysis with age, gender, 
KPS, re-resection prior to ACNU and dexamethasone treatment (yes/no) as covariables. SPSS 
software version 15.0 was used for statistical analysis. 
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Results 
 
Table 1 summarizes essential patient characteristics. 30 glioblastoma patients were treated at 
first and 2 glioblastoma patients at further relapse or progression. Twenty-six patients died 
until closure of the data base. The median number of cycles was 2 (range: 1-6). Six patients 
received only one cycle, 4 completed >4 cycles, 20 were on steroids when starting ACNU. 
The median dexamethasone dose of these was 5 mg/d (range 1-18 mg/d).  
 
Toxicity 
Sixteen patients (50%) developed CTCAE grade 3/4 hematotoxicity. Twelve patients (38%) 
displayed CTCAE grade 3/4 leukocytopenia and nine patients (29%) grade 3/4 
thrombocytopenia. Of these 16 patients, 9 received a combination of ACNU and teniposide, 
in one patient ACNU was combined with cytarabine and 6 patients received only ACNU.  
The dose of one or more drugs was reduced because of myelosuppression in 12 patients 
(38%). No patient developed neutropenic fever, 4 required cytokine support, and 4 had 
transfusions at least once. Other adverse events were documented in 7 patients: nausea (n=2, 
CTCAE grade 2), vomiting (n=1, grade 2), fatigue (n=1, grade 2), generalized herpes zoster 
reactivation (n=1, grade 3), wound healing disorder (n=1, grade 3) and increase of liver 
enzymes (n=1, grade 3). There was no instance of lung fibrosis according to clinical 
examinations or spirometry. One patient developed leukencephalopathic changes documented 
by MRI that were considered radiochemotherapy-related, but were asymptomatic in routine 
clinical examination without detailed neuropsychological testing. Chemotherapy was stopped 
in 7 patients because of adverse events: 4 for hematological toxicity, 1 for generalized herpes 
zoster reactivation, 1 for wound healing disorder and 1 for increase of liver enzymes. 
 
Efficacy 
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Magnetic resonance imaging (MRI) or computed tomography (CT) were performed in 2-3 
months intervals. There were 2 partial remissions (PR) (6%), but no complete remissions 
(CR). Stable disease (SD) was achieved in 5 patients (16%). The median PFS (mPFS) from 
start of ACNU was 2.7 months (95% CI: 2.49-2.90). PFS at six months (PFS-6) was 20% (2 
censored cases). The median OS from the start of ACNU therapy was 6.7 months (95% CI: 
3.35-10.1; 6 censored cases). The survival rates were 26% at one year (5 censored cases) and 
12% at two years (5 censored cases) (Figure 1). Age, KPS (>80% or 80%), co-medication 
with steroids, a re-resection or degree of re-resection prior to ACNU chemotherapy were not 
associated with time to progression or survival in a log-rank analysis. None of these factors 
was identified as an independent risk factor in a multivariate Cox-regression analysis. Further, 
in a univariate log-rank or a multivariate Cox-regression analysis, the co-medication with 
teniposide had no statistical impact on progression-free (p = 0.286 and p = 0.415, Wald = 
0.664) or overall (p = 0.736 and p = 0.949, Wald = 0.04) survival. When forming prognostic 
subclasses of the patients as suggested by Carson et al. [13], most patients were classified in 
group 7 (Table 2). This analysis favours an ACNU-based therapy in prognostic classes 4-6, 
but the number of patients in these subclasses may be too small to draw final conclusions. 
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Discussion 
The EORTC 26981-22981/NCIC CE3 trial established temozolomide as the first-line therapy 
of glioblastoma [1]. There is no such gold standard for the treatment at progression or 
recurrence. In this retrospective study, we analyzed the outcome of 32 patients with recurrent 
glioblastoma who were treated with ACNU-based chemotherapy.  
There was a relevant hematotoxicity (CTCAE grade 3/4) of ACNU-based chemotherapy in 16 
patients (50%). Treatment had to be stopped in 3 patients because of non-hematological 
toxicity. Moreover, the frequency of adverse events is commonly underestimated in 
retrospective series. 
In a large meta-analysis, chemotherapy for recurrent glioblastoma resulted in a PFS of nine 
weeks, a PFS-6 of 15% and a survival rate of 21% at 1 year (OS-1) [14].  A more recent meta-
analysis confirmed these data with a PFS-6 of 16% and an OS-1 of 25% [15]. The latter 
analysis confirmed the importance of PFS-6 as a reliable endpoint for studies in recurrent 
gliomas. In the registration trial, temozolomide given at recurrence in a conventional 
treatment schedule induced a progression-free survival of 11 weeks and a PFS-6 of 21% [16]. 
A recent phase II study using a weekly alternating schedule of dose-intensified temozolomide 
(one week on/one week off) led to a median survival of 24 weeks and a PFS-6 of 44% [17]. In 
the latter study, patients who had received temozolomide as a first-line therapy benefited from 
a dose-intensified re-exposure, too. Another phase II study evaluated the use of bevacizumab, 
a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan, 
a topoisomerase inhibitor [18, 19]. This study reached a PFS-6 of 46% in patients with 
recurrent glioblastoma. Although the role of nitrosoureas, namely ACNU, BCNU or CCNU in 
recurrent glioblastoma has been established, most of these data concern patients that had not 
been preexposed to temozolomide. Brandes et al. performed a phase II study with a 
combination therapy of procarbazine, BCNU and vincristine (PBV) and achieved a PFS-6 of 
42% [9]. However, the patients enrolled in this study were chemonaive. In a retrospective 
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analysis of patients with recurrent glioblastoma treated with procarbazine, CCNU and 
vincristine, a median PFS of 17 weeks and a PFS-6 of 38% were observed [11]. In the latter 
study, 62% of patients had previous chemotherapy but only 15% had been preexposed to 
temozolomide. 
In the present study, an ACNU-based chemotherapy resulted in a PFS-6 of 20%. This PFS 
rate is poorer than that observed with the PBV or PCV regimens, but is similar to that 
observed with BCNU alone. However, results from other studies are difficult to compare 
because of differing subgroups of patients and risk factor profiles. Patient characteristics in 
this study do not suggest a population of patients excessively enriched for negative prognostic 
factors in terms of age or KPS with a preponderance of male patients (75%). The distribution 
of patients and the median OS according to the subgroups proposed by Carson et al. largely 
confirms the original publication [13] with a tendency towards a better prognosis in 
subgroups 4 to 6. However, the number of patients in these subgroups was rather small which 
limits the interpretation of this finding. The subgroup 7 resumes most of the patients and the 
median survival in this group corresponds well to the data base. Thus, the relatively poor 
results in this study could be due to the fact that the combination partners in the PBV and 
PCV regimens contribute to this efficacy or that temozolomide pre-treated patients are less 
likely to respond to nitrosoureas at recurrence. Altogether, treatment results with ACNU are 
inferior compared with the recent studies with bevacizumab/irinotecan [18, 19] or dose-
intensified temozolomide [17] and also showed considerable hematotoxicity. We do not 
propose that our data exclude a role of ACNU in certain subgroups of patients or within 
combined treatments in recurrent glioblastoma. However, in the era of temozolomide as the 
first-line therapy of glioblastoma, these data can not recommend ACNU as the agent of first 
choice at progression or recurrence in terms of tolerability and efficacy.  
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Table 1: Patient characteristics. 
 
 Number 
of 
patients 
Percentage 
(%) 
Age, years 
Median 
Range 
 
60 
33-78 
  
Sex 
Male 
Female 
 
 
24 
8 
 
75 
25 
Surgery at relapse prior to ACNU 
- extent unknown 
- partial resection 
- complete resection 
 
15 
2 
10 
3 
46.9 
6.3 
31.3 
9.4 
Previous (chemo-)therapy 
Temozolomide  
- dose-intensified (one week on/one  
week off) 
- standard (5/28) 
- in combination with CCNU 
- in combination with cilengitide 
- in combination with indometacine 
32 
32 
13 
 
13 
4 
2 
1 
 
100 
100 
40.6 
 
40.6 
12.5 
6.4 
3.1 
 
Karnofsky performance status at 
initiation of ACNU 
100 
90 
80 
70 
60 
 
 
 
       5 
12 
6 
8  
1 
 
 
 
       15.6 
37.5 
18.8 
25 
3.1 
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Table 2: Comparison of median survival according to prognostic subgroups as suggested by 
Carson et al. Group 4: age < 50, KPS 90-100. Group 5: age < 50, KPS 60-80. Group 6: age ≥ 
50, no steroids. Group 7: age ≥ 50, with steroids [13]. Six censored cases. 
 
Prognostic 
subgroup 
Carson et al. 
Patients (n; %)        median survival 
                                     [months] 
This study 
Patients (n; %)        median survival 
                                     [months] 
4 48 (23%) 10.4 4 (15%) 13.1 
5 35 (17%) 5.6 2 (8%) 6.7 and 8.6 
6 28 (13%) 6.4 5 (19%) 10.2 
7 99 (47%) 4.9 15 (58%) 4.6 
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Figure 1: Progression-free and overall survival of 32 patients with recurrent glioblastoma 
treated with an ACNU-based chemotherapy (6 and 5 censored cases respectively). 
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